. Author manuscript; available in PMC: 2021 Aug 2.

Published in final edited form as: J Pathol. 2019 Nov 29;250(2):148–158. doi: 10.1002/path.5353

Table 1.

Mutation status of endosalpingiotic lesions associated with synchronous or metachronous ovarian low-grade serous tumour

Case ID	Ovarian tumour		Endosalpingiosis
Case ID	Type (stage)	Genotype	Site	Genotype	MAF

1	SBT (II)	BRAF^V600E	Lymph node (Es #1 - simple)	BRAF^V600E	54%
			Lymph node (Es #2 - florid)	BRAF^V600E	58%
2	SBT (II)	BRAF^V600E	Ovary (inclusion cysts)^*	BRAF^V600E	38%
3	LGSC (III)	BRAF^V600E	Peritoneum	BRAF^V600E	58%
4	Micropapillary SBT (III)	BRAF^V600E	Peritoneum	BRAF^V600E	67%
5	Micropapillary SBT (II)	BRAF^V600E	Lymph node	WT	–
6	SBT	BRAF^V600E	Peritoneum	WT	–
7	SBT (I)	BRAF^V600E	Peritoneum	WT	–
8	SBT (I)	BRAF^V600E	Lymph node (Es #1)	WT	–
			Lymph node (Es #2)	WT	–
			Omentum	WT	–
9	SBT (II)	KRAS^G12V	Lymph node (Es #1 - simple)	KRAS^G12V	36%
			Lymph node (Es #2 - florid)	KRAS^G12V	25%
10	LGSC (IV)	KRAS^G12D	Lymph node	KRAS^G12D	43%
11	SBT (I)	KRAS^G12D	Ovary (inclusion cysts)	KRAS^G12D	14%
12	SBT (I)	KRAS^G12D	Ovary (inclusion cysts)	KRAS^G12D	19%
13^‡	SBT (II)	KRAS^G12D	Peritoneum	KRAS^G12D	32%
14	SBT (II)	KRAS^G12D	Peritoneum	KRAS^G12D	43%
15	SBT (I)	KRAS^G12V	Lymph node	WT	–
16	SBT (III)	KRAS^G12D	Peritoneum (within noninvasive implant)^†	WT	–
17	SBT (III)	KRAS^G12D	Peritoneum	WT	–
18	Micropapillary SBT (I)	WT	Omentum (Es #1)	WT	–
			Omentum (Es #2)	KRAS^G12D+ KRAS^G12V	G12D: 12%; G12V: 13%
19	SBT	WT	Lymph node	WT	–
20	Micropapillary SBT (III)	WT	Lymph node	WT	–
21	SBT (I) (focally arising in cystadenofibroma)	WT	Lymph node #1	WT	–
			Lymph node #2	WT	–
			Lymph node #3	WT	–

WT, wildtype.

Adjacent focus of tumour auto-implant also positive for BRAF^V600E (MAF 57%).

^†

Subclonal KRAS^G12D (MAF 10%) detected in tumour cells within the implant.

^‡

KRAS^G12V (MAF 1.9%) and KRAS^G12D (MAF 0.8%) detected in eutopic Fallopian tube.